Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this clinical trial is to learn whether fish oil-based supplements can affect gene expression and serum protein markers in healthy volunteers. The main questions it aims to answer are:
Researchers will compare two types of fish oil supplements. One type contains fish oil and wild orange essential oil as its active ingredients. The other type contains only fish oil as its active ingredient.
Participants will:
This randomized, double-blind study will recruit healthy adults to compare gene expression profile, omega-3 levels, and protein markers before and after consumption of fish oil supplements for approximately six weeks. Quality of life will also be assessed using subjective surveys and questionnaires. Safety markers (liver and kidney function, hematology, urinalysis, and adverse events) will be collected.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Fish oil + wild orange essential oil supplement | Experimental | Participants in this arm will take three capsules of a fish oil + wild orange essential oil supplement daily for approximately six weeks. |
|
| Fish oil supplement | Active Comparator | Participants in this arm will take three capsules of a fish oil essential oil supplement daily for approximately six weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Fish oil + wild orange essential oil supplement | Dietary Supplement | This supplement contains fish oil and wild orange essential oil as its active ingredients. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Gene expression | Gene expression analysis refers to a genome-wide quantification of methylation. EPIC850k array will be used for methylation analysis. This represents approximately 900,000 gene locations. The main feature performed is a differential methylation analysis to determine what has significantly changed from one time point to another. | 6 weeks |
| Interleukin 6 (pg/mL) | Serum marker for inflammation | 6 weeks |
| High sensitivity C-reactive protein (mg/L) | Serum marker for inflammation and cardiac health | 6 weeks |
| Apolipoprotein B (mg/dL) | Serum marker for cardiovascular disease risk | 6 weeks |
| Total cholesterol (mg/dL) | Item in lipid panel for efficacy assessment | 6 weeks |
| Triglycerides (mg/dL) | Item in lipid panel for efficacy assessment | 6 weeks |
| High density lipoprotein (HDL) Cholesterol (mg/dL) | Item in lipid panel for efficacy assessment | 6 weeks |
| Very Low density lipoprotein (VLDL) Cholesterol (mg/dL) | Item in lipid panel for efficacy assessment |
| Measure | Description | Time Frame |
|---|---|---|
| Albumin (g/dL) | Item in comprehensive metabolic panel for safety assessment | 6 weeks |
| Blood urea nitrogen (BUN) (mg/dL) | Item in comprehensive metabolic panel for safety assessment |
Not provided
Inclusion Criteria:
Males and females, 18-64 years old
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nicole Stevens, PhD | doTERRA International | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| doTERRA International | Pleasant Grove | Utah | 84062 | United States |
Not provided
| ID | Term |
|---|---|
| D005395 | Fish Oils |
| ID | Term |
|---|---|
| D009821 | Oils |
| D008055 | Lipids |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Fish oil supplement | Dietary Supplement | This supplement contains fish oil as its active ingredient. |
|
| 6 weeks |
| Low density lipoprotein (LDL) Cholesterol (mg/dL) | Item in lipid panel for efficacy assessment | 6 weeks |
| Omega-3 blood levels (%) | Assessment of omega-3 fatty acid concentration in blood | 6 weeks |
| 6 weeks |
| Creatinine (mg/dL) | Item in comprehensive metabolic panel for safety assessment | 6 weeks |
| Alkaline phosphatase (U/L) | Item in comprehensive metabolic panel for safety assessment | 6 weeks |
| Alanine transaminase (ALT) (U/L) | Item in comprehensive metabolic panel for safety assessment | 6 weeks |
| Aspartate aminotransferase (AST) (U/L) | Item in comprehensive metabolic panel for safety assessment | 6 weeks |
| Calcium (mg/dL) | Item in comprehensive metabolic panel for safety assessment | 6 weeks |
| Carbon Dioxide (mmol/L) | Item in comprehensive metabolic panel for safety assessment | 6 weeks |
| Chloride (mmol/L) | Item in comprehensive metabolic panel for safety assessment | 6 weeks |
| Potassium (mmol/L) | Item in comprehensive metabolic panel for safety assessment | 6 weeks |
| Sodium (mmol/L) | Item in comprehensive metabolic panel for safety assessment | 6 weeks |
| Total bilirubin (mg/dL) | Item in comprehensive metabolic panel for safety assessment | 6 weeks |
| Total protein (g/dL) | Item in comprehensive metabolic panel for safety assessment | 6 weeks |
| Body mass index (BMI) | Determine whether body mass index is affected by the consumption of the study product. | 6 weeks |
| Blood pressure (mmHg) | Determine whether blood pressure is affected by the consumption of the study product. | 6 weeks |
| Heart rate (BPM) | Determine whether heart rate is affected by the consumption of the study product. | 6 weeks |
| White blood cells (x10E3/uL) | Item in complete blood count for safety assessment | 6 weeks |
| Red blood cells (x10E6/uL) | Item in complete blood count for safety assessment | 6 weeks |
| Hemoglobin (g/dL) | Item in complete blood count for safety assessment | 6 weeks |
| Hematocrit (%) | Item in complete blood count for safety assessment | 6 weeks |
| Mean corpuscular volume (fL) | Item in complete blood count for safety assessment | 6 weeks |
| Mean corpuscular hemoglobin (pg) | Item in complete blood count for safety assessment | 6 weeks |
| Mean corpuscular hemoglobin concentration (g/dL) | Item in complete blood count for safety assessment | 6 weeks |
| Red cell distribution width (%) | Item in complete blood count for safety assessment | 6 weeks |
| Platelets (x10E3/uL) | Item in complete blood count for safety assessment | 6 weeks |
| Neutrophils (%) | Item in complete blood count for safety assessment | 6 weeks |
| Lymphocytes (%) | Item in complete blood count for safety assessment | 6 weeks |
| Monocytes (%) | Item in complete blood count for safety assessment | 6 weeks |
| Eosinophils (%) | Item in complete blood count for safety assessment | 6 weeks |
| Basophils (%) | Item in complete blood count for safety assessment | 6 weeks |
| Neutrophils (Absolute) (x10E3/uL) | Item in complete blood count for safety assessment | 6 weeks |
| Lymphocytes (Absolute) (x10E3/uL) | Item in complete blood count for safety assessment | 6 weeks |
| Monocytes (Absolute) (x10E3/uL) | Item in complete blood count for safety assessment | 6 weeks |
| Basophils (Absolute) (x10E3/uL) | Item in complete blood count for safety assessment | 6 weeks |
| Immature granulocytes (%) | Item in complete blood count for safety assessment | 6 weeks |
| Immature granulocytes (Absolute) (x10E3/uL) | Item in complete blood count for safety assessment | 6 weeks |
| Safety/tolerability | This study will monitor the occurrence and frequency of adverse events and safety, both through participant report and blood chemistry/hematology analyses. | 6 weeks |
| Generalized Anxiety Disorder-7 (GAD-7) scale | Self-reported scale for the measurement of anxiety severity | 6 weeks |
| Patient Health Questionnaire (PHQ-8) scale | Self-reported scale for the measurement of depression severity | 6 weeks |
| Leeds Sleep Evaluation Questionnaire (LSEQ) scale | Self-reported scale for the measurement of sleep quality | 6 weeks |
| Short Form-20 (SF-20) scale | Self-reported scale for assessment of subjective quality of life | 6 weeks |